Among those tested, anti-GAD antibodies were detected with ELISA—but not CBA—in low (< 2000 IU/ml) titers, as typically seen in Type-I diabetes, but not > 2000 IU/ml, as seen in GAD-spectrum neurological disorders [17]. Here, GAD1 is linked to nervous system disorder.